Supernus Acquires Apokyn and Xadago from US WorldMeds

Supernus Acquires Apokyn and Xadago from US WorldMeds
5
(9)

Supernus Pharmaceuticals’ acquisition of US WorldMeds’ portfolio of central nervous system (CNS) disease treatments adds two established Parkinson’s disease (PD) therapies and a leading investigative product to its neurology portfolio.

The deal calls for a $300 million upfront cash outlay, plus $230 million in milestone payments for the Parkinson’s treatments Apokyn (apomorphine) and Xadago (safinamide).

Supernus also acquired the company’s Apomorphine Infusion Pump, which, if approved by the U.S. Food and Drug Administration (FDA), would allow for a continuous subcutaneous (under the skin) apomorphine infusion.

“This acquisition aligns extremely well with our strategy of expanding and enhancing our commercial and late-stage assets and is a significant step in strengthening our leadership position in CNS,” Jack Khattar, Supernus’ president and CEO, said in a press release.

It also “brings new research and development platforms to Supernus in biologics and medical devices. We look forward to building on the success that US WorldMeds had in establishing this portfolio of unique products.”

Apokyn is given by injection between doses of the levodopa to treat a loss of body movement control in patients with advanced Parkinson’s. It has the same effect as dopamine, a naturally occurring chemical messenger in the brain that is gradually lost in the disease.

Several years after starting levodopa — a gold standard in care — most patients begin experiencing motor symptom fluctuations caused by a faster wearing off of the treatment’s effects. These “off” episodes can happen at any time of the day, and most patients experience more than one episode daily. In a Michael J. Fox Foundation survey of 3,000 patients, more than 90 percent reported having at least one “off” episode daily, and nearly 65 percent experienced such episodes for at least two hours.

Apokyn does not prevent off episodes, but it does help to improve symptoms when an episode has begun.

Xadago is an oral once-daily add-on therapy developed to improve motor function in Parkinson’s patients experiencing off periods. It works through the selective and reversible inhibition of the enzyme monoamine oxidase B, which increases functional dopamine levels. It also blocks voltage-dependent sodium channels, which regulate the release of abnormal glutamate, a neurotransmitter in the brain involved in nerve cell communication. The treatment is available in several countries, including the United States.

If approved by the FDA, the Apomorphine Infusion Pump would offer Parkinson’s patients a less-invasive and more convenient way to administer Apokyn. The device would provide a continuous subcutaneous infusion of the medication.

Supernus is expected to submit an application to the FDA requesting approval this year, likely supported by findings in a Phase 3 trial of the pump’s use (NCT02339064) in patients. If approved, the product could launch in the second half of 2021.

“The core values of Supernus align very well with US WorldMeds,” said Paul Breckinridge Jones Sr., CEO of US WorldMeds. “We expect a seamless transition with even more patients benefiting from these products under Supernus’ stewardship. This transaction will allow US WorldMeds to focus on growing our other exciting business units.”

This CNS portfolio, which includes the cervical dystonia therapy Myobloc (rimabotulinumtoxinB), had net sales last year of about $150 million. Under the agreement, Supernus will also gain a sales team with expertise in serving movement disorder specialists in the U.S.

Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Total Posts: 208
Ana holds a PhD in Immunology from the University of Lisbon and worked as a postdoctoral researcher at Instituto de Medicina Molecular (iMM) in Lisbon, Portugal. She graduated with a BSc in Genetics from the University of Newcastle and received a Masters in Biomolecular Archaeology from the University of Manchester, England. After leaving the lab to pursue a career in Science Communication, she served as the Director of Science Communication at iMM.
×
Mary M. Chapman began her professional career at United Press International, running both print and broadcast desks. She then became a Michigan correspondent for what is now Bloomberg BNA, where she mainly covered the automotive industry plus legal, tax and regulatory issues. A member of the Automotive Press Association and one of a relatively small number of women on the car beat, Chapman has discussed the automotive industry multiple times of National Public Radio, and in 2014 was selected as an honorary judge at the prestigious Cobble Beach Concours d’Elegance. She has written for numerous national outlets including Time, People, Al-Jazeera America, Fortune, Daily Beast, MSN.com, Newsweek, The Detroit News and Detroit Free Press. The winner of the Society of Professional Journalists award for outstanding reporting, Chapman has had dozens of articles in The New York Times, including two on the coveted front page. She has completed a manuscript about centenarian car enthusiast Margaret Dunning, titled “Belle of the Concours.”
Latest Posts
  • Acadia and MJFF
  • Parkinson's Foundation and Alexa
  • PD GENEration
  • non-motor symptoms

How useful was this post?

Click on a star to rate it!

Average rating 5 / 5. Vote count: 9

No votes so far! Be the first to rate this post.

As you found this post useful...

Follow us on social media!

We are sorry that this post was not useful for you!

Let us improve this post!

Tell us how we can improve this post?